
The FDA approves VOCERYQ, the first DNA medicine, for RRP surgery reduction, raising plasmid, drug-device, and confirmatory trial manufacturing demands.
SI Group agrees to purchase certain Albemarle assets and products.
The acquisition will include Albemarle’s antioxidant product lines, as well as the Ibuprofen and Propofol businesses. In addition, applications and technical support capabilities in Shanghai and Baton Rouge, Louisiana will be included in the transaction. Subject to the required regulatory approvals, this acquisition is expected to be completed later this year.
Source:






